Biotech Breakthroughs in Anti-Aging: Decoding the Hallmarks of Aging and the Longevity Code
HONG KONG SAR - Media OutReach Newswire - 16 July 2025 - From the popularity of anti-aging supplements and aesthetic treatments to Silicon Valley billionaires' pursuit of immortality, the global wave of anti-aging is gaining momentum, and Hong Kong is no exception. Questions like 'How to stay young?', 'Is NMN really effective?' and 'At what age should you start anti-aging care?' have become part of everyday conversation. While many are eager to delay the signs of aging, few truly understand the science behind it.
Dr Fred Zülli (second from right), Founder and Business Development Director of Mibelle Biochemistry, Francis Kwan (second from left), President of HKSCC, Cirrus Chu (first from left), Sales Director of TPMC International Limited and Fanny Cheung (first from right), Director of NF Essential Limited attended the anti-aging seminar.
From Hallmarks of Aging to Scientific Action: Effective Solutions Revealed
To address this knowledge gap, Dr. Fred Zülli, Founder and Business Development Director of Swiss-based biotech company Mibelle Biochemistry, was specially invited to Hong Kong to co-host a seminar with the Hong Kong Society of Cosmetic Chemists. The seminar provided an in-depth look at the latest advancements in Swiss anti-aging research, starting with the 12 'Hallmarks of Aging' theory published in the journal Cell. Dr. Zülli explained how Swiss biotechnology is strategically targeting these biological mechanisms of aging and translating scientific breakthroughs into practical applications in skincare and aesthetic medicine, making age-defying solutions a scientific reality rather than a distant ideal. During the seminar, Dr. Zülli also revealed several truly effective, science-backed methods to combat aging.
Next-Gen Skincare Science: Goji Stem Cell Extract with Dual Action Power for Repair
Exosomes have rapidly emerged as one of the most promising technologies in the skincare industry. According to market data, the global exosome market was valued at over US$140 million in 2023 and is projected to expand at 28% CAGR by 2030. In the U.S., Google searches for 'exosomes' surged 17% in one year, evidence of rising consumer interest. Dr. Fred Zülli explains that exosomes are tiny vesicles that are released by cells into the extracellular space, rich in proteins, lipids, and nucleic acids. They can be derived from human, animals or plants cells, including plant stem cells, and reconstructed using liposome technology. These 'cellular messengers' play key roles in intercellular communication, immune modulation, and drug delivery. When used in skincare or microneedling treatments, they accelerate wound healing, enhance skin regeneration, and deliver deeper, faster, and safer results. Exosomes offer dual benefits: they strengthen the skin barrier while activating deeper cellular repair, improving overall skin quality, reducing fine lines, and restoring firmness for true inside-out anti-aging effects.
Clinically Proven Plant Stem Cells Go Beyond Surface-Level Skincare
Swiss researchers at Mibelle have developed the PhytoCellTec™ Exosomes technology, using natural Goji Stem Cell Extract to stimulate exosome production. This powerful natural ingredient demonstrates 'dual action', promoting keratinocyte differentiation and the expression of epidermal growth and antioxidant-related genes to reinforce the skin's outer barrier.
Meanwhile, it reactivates mesenchymal stem cells (MSCs), boosting collagen synthesis and cellular vitality to enhance skin elasticity and density. Clinical studies show that a cream containing just 0.4% of Goji Stem Cell Extract significantly reduces fine lines and wrinkles after 56 days. Results can be seen in just 28 days with improved skin density and facial contour, and even firmness and lifting effects when applied to the breast area, showcasing its applications well beyond facial skincare.
Exosomes in Daily Skincare and Medical Aesthetics
With proven regenerative and wound-healing properties, exosomes are emerging as a viable alternative to stem cell therapies. As non-living biological elements, they are more stable and easier to handle. Exosome-based serums are particularly effective when used with microneedling, enabling deep skin repair and faster healing.
Plant-derived exosomes have been shown to be bioavailable to mammalian cells and exhibit anti-inflammatory, antioxidant, anti-tumour, and skin-repairing benefits. Recent studies confirm their ability to combat skin aging, reinforcing their growing role in both cosmetic dermatology and everyday skincare. As this technology evolves, it promises a new era of personalized, science-backed beauty.
Dual Stem Cell Formula: 'Swiss StemGlow Jelly' Nourishes Youthful Skin from Within; The brand 'LAB 91" Unveils Advanced Microneedle Skincare Powered by Deep Cellular Repair
The Swiss StemGlow Jelly is an edible functional jelly formulated with dual stem cell active ingredients, Swiss apple stem cells and grape stem cells. These ingredients are renowned for enhancing cellular vitality, delivering antioxidant protection, and shielding the skin from UV damage.
Meanwhile, LAB 91, a Swiss-made brand, specializes in microneedle skincare solutions. Its signature innovation, the Dual Plant Stem Cell Exosome Complex, combines rare Swiss apple stem cells with goji stem cells to deeply penetrate the skin and trigger cellular repair. Proven results include improved skin elasticity, lifted facial contours, and visibly diminished wrinkles.
The brand offers a range of ampoule serums tailored to various skin concerns, including anti-aging, brightening and intensive repair. Together, the edible jelly and topical microneedle treatments deliver synergistic, cell-level rejuvenation from the inside out.
Hashtag: #ESDLife
The issuer is solely responsible for the content of this announcement.
About ESDlife
ESDlife, a joint venture of CK Hutchison (formerly Hutchison Whampoa) and Hewlett-Packard HK SAR, operates the award-winning website ( www.esdlife.com ) and establishes it as one of the most popular and trusted online lifestyle media in Hong Kong. The online platform of ESDlife is furnished with a wide range of lifestyles information under the categories of Wedding, Family and Health. In addition to the prominent No. 1 position of its Wedding Channel in Hong Kong, an e-commerce platform is provided to consumers by offering medical check-up ordering services. ESDlife also delivers integrated marketing and digital solutions to diversified corporate clients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
New Study in JAMA Network Open Shows Current Approaches to Assessing Preeclampsia Risk Are Failing the Majority of Pregnant Moms
By relying on maternal characteristics and broad demographics, guidelines identify 9 out of 10 pregnancies at increased risk, resulting in ineffective preventive care SOUTH SAN FRANCISCO, Calif., July 17, 2025--(BUSINESS WIRE)--A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there's limited value for the moderate risk category - leading to nonspecific recommendations for aspirin use, a recognized prevention tool. This cohort study of 5684 participants, culled from the multi-center Miracle of Life prospective study, found the guidelines identified nearly 89% of pregnancies at increased risk of preeclampsia. 70.3% were in the moderate risk category, defined by maternal characteristics and broad demographics including age, body mass index, and race, while 18.5% were in the high risk category, which includes patients with conditions like chronic hypertension or prior history of preeclampsia. The study findings suggest that the murkiness of moderate risk factors may influence clinicians' decisions regarding daily aspirin recommendations. While 82% of women with a high risk factor were recommended daily aspirin, only 37% of those with one or more moderate risk factors were given this recommendation. USPSTF, American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) all endorse guidance to consider or recommend starting aspirin between 12 to 28 weeks' gestation for pregnancies with moderate risk factors. "Identifying 9 out of 10 women as at risk is not helping and overburdens care teams and pregnant patients, too," said Dr. Thomas McElrath, vice president of clinical development at Mirvie and a practicing maternal-fetal medicine physician at Mass General Brigham, as well as lead author of the study. "Physicians may be reluctant to prescribe aspirin when the majority of their patients fall into the moderate risk category. This is compounded by less than 25% compliance with aspirin use by patients in the moderate risk category." Most pregnant women in the study (70.3%) fell into the moderate risk category using the USPSTF guidelines, but having one or more moderate risk factors and no high-risk factors were not predictive of preeclampsia risk. Among individuals with 2 or more moderate risk factors but without any high risk factor, nulliparity was associated with modestly increased risk of preeclampsia (RR, 1.48; 95% CI, 1.35-1.62; P < .001); there was little or no association with obesity (RR, 1.11; 95% CI, 1.01-1.22; P = .048), Black race (RR, 0.95; 95% CI, 0.80-1.14; P = .63), and advanced maternal age (RR, 0.79; 95% CI, 0.65-0.96; P = .02). "Rates of preeclampsia in the US have doubled in the past 15 years and continue to rise with no end in sight," said Kara Boeldt, a preeclampsia survivor and Founder and Executive Director of "The introduction of the USPSTF guidelines in 2021 didn't do anything to reverse course on the rise of preeclampsia. This important and eye-opening study highlights that we need new approaches that can predict who's truly at risk for preeclampsia, which can be so dangerous for moms and their babies. This is why I am incredibly encouraged and excited by the innovation being led by companies like Mirvie, which can finally offer some pregnant women and their care teams a clear, personalized prediction of their preeclampsia risk with a simple blood test during pregnancy." "The findings of this important study confirm the need for clear, objective measures of preeclampsia risk prediction, to motivate preventive care," said Maneesh Jain, CEO and co-founder of Mirvie. "With innovation like Encompass™, we can now deliver preventive care to the right patients at the right time and impact rates of preterm birth." About the Miracle of Life study The Mirvie-sponsored Miracle of Life study examined nearly 11,000 pregnancies across the U.S., including 22,000 cell-free RNA transcripts per patient which resulted in 200 million data points overall, making it the largest study of molecular health in pregnancy of its kind. The landmark research study on pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine, uncovers how RNA messages present in expectant mothers' blood can predict life-threatening pregnancy complications. One area of study relates to cell-free RNA's prediction of preeclampsia months in advance, a leading cause of pregnancy-related morbidity and mortality. About Mirvie Mirvie is bringing scientifically rigorous and data-driven approaches to solving some of the most pressing clinical problems in women's health, beginning with pregnancy. Serious complications impact one in five pregnancies in the U.S., and Mirvie is committed to creating a world where every pregnancy is as safe and healthy as possible. Founded and led by a team of seasoned entrepreneurs and scientists, the company is based in South San Francisco, California and backed by top-tier investors including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield. For more information, visit View source version on Contacts Press contact:Kate Enoskate@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Dementia Linked With Treatment For Chronic Lower Back Pain
A drug widely used to treat nerve pain and epilepsy has been linked with an increase in cases of dementia and mild cognitive impairment. A team from Case Western Reserve University School of Medicine, Arizona State University, and the MetroHealth Medical Center in the US crunched the numbers on 26,416 records of patients with chronic lower back pain, looking at the relationship between prescriptions for the anticonvulsant gabapentin and dementia diagnoses. Having six or more gabapentin prescriptions was linked to a significant increase in dementia risk and mild cognitive impairment (MCI), the data showed: those in that group were 29 percent and 85 percent more likely to be diagnosed with dementia and MCI respectively, within 10 years. Related: Massive Study Links 15 Factors to Early Dementia Risk The increase was higher among patients aged between 35 and 49, and also rose with the number of prescriptions given, the researchers found. Though the study can't establish a cause for the increase, physicians are encouraged to keep a close eye on patients taking the drug. "Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults," write the researchers in their published paper. "Physicians should monitor cognitive outcomes in patients prescribed gabapentin." Sold under brand names including Neurontin, gabapentin has proved to be less addictive than opioids, making it more likely to be prescribed in recent years. The drug does have some known side effects though, including extreme moods and allergic reactions. This isn't the first time researchers have examined associations between gabapentin and dementia, but previous studies haven't agreed on whether or not concerns are warranted. One of the study's strengths is the relatively large sample size of its participants, though the sample largely consisted of just one group of people – those with chronic lower back pain. A study published in 1997 found no link between gabapentin and cognitive decline in people with epilepsy, so it's important to continue to widen the data set. These conflicting results could suggest unique mechanisms among patients with the type of backpain that leads to a gabapentin prescription that also increases their risk of dementia, like a certain type of location of inflammation. But gabapentin works by dampening some of the brain's key communication channels, in order to provide relief from pain or make seizures less likely. So the worry is that it could also be damaging links between neurons in ways that might lead to dementia – a concern backed up by this latest study. Dementia is a challenging condition to study with so many potential factors to account for, but each study gets us closer to the full picture of how the brain breaks down over time. "We hope the current study promotes further research to delineate whether gabapentin plays a causal role in the development of dementia and the underlying mechanisms of this relationship," write the researchers. The research has been published in Regional Anesthesia & Pain Medicine. Related News 8 Babies Born in UK Using Radical 'Three Parent' IVF Technique These 4 Simple Exercises Could Help Break Your Insomnia Energy Drinks Seen Fuelling Cancer, But There's a Strange Catch Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Dramatic rise in gastrointestinal cancers in people under 50
There has been a dramatic rise in gastrointestinal cancers in people under the age of 50, according to a new review. Gastrointestinal cancers, such as colorectal cancer and pancreatic cancer, 'represent the most rapidly increasing early-onset cancer in the US,' researchers wrote in a review published in The Journal of the American Medical Association (JAMA) Thursday. Colorectal cancer, which develops in the colon or rectum, was the most common among early-onset gastrointestinal cancers in the U.S. in 2022, with just over 20,800 people diagnosed. There were 2,689 diagnoses of Gastric cancer, which develops in the stomach lining, that year, followed by 2,657 diagnoses of pancreatic cancer and 875 diagnoses of esophageal cancer. There has been a dramatic rise in gastrointestinal cancers in people under the age of 50, according to a new review (Getty Images) Most early-onset gastrointestinal cancers are linked to risk factors that could be changed, such as obesity, poor-quality diet, and a somewhat inactive lifestyle. Smoking cigarettes and drinking alcohol are other risk factors. 'It's really what people were doing or exposed to when they were infants, children, adolescents that is probably contributing to their risk of developing cancer as a young adult,' Dr. Kimmie Ng, the review's co-author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute, told NBC News. There are also risk factors that patients don't have control over such as family history and hereditary syndromes. People with early-onset colorectal cancer could have inflammatory bowel disease. Researchers wrote in the review: 'The prognosis for patients with early-onset GI cancers is similar to or worse than that for patients with later-onset GI cancers, highlighting the need for improved methods of prevention and early detection.' The American Cancer Society recommends people at average risk of colorectal cancer start regular screening at the age of 45. Before 2018, the ACS recommended screenings start at the age of 50. 'It never used to happen in this age group, and now a very significant rise in 20-, 30- and 40-year-olds are getting colon cancer,' Dr. John Marshall, chief medical consultant at the nonprofit Colorectal Cancer Alliance, who was not involved in the review, told NBC News. It's still unclear why young patients with gastrointestinal cancers could have worse survival rates than older patients. 'My personal feeling is that it's because we're finding them at a more advanced stage, because people don't really think of colon or other GI cancers when they see a young person with these nonspecific complaints,' Dr. Howard Hochster, director of gastrointestinal oncology at Rutgers Cancer Institute and RWJBarnabas Health in New Jersey, who was not involved in the review, told NBC News. But Ng said even when taking the stage of cancer into account, young patients still seem to have worse survival rates, and questioned whether there's a biological reason.
